224 related articles for article (PubMed ID: 23507276)
1. In vitro and in vivo efficacy of β-lactams against replicating and slowly growing/nonreplicating Mycobacterium tuberculosis.
Solapure S; Dinesh N; Shandil R; Ramachandran V; Sharma S; Bhattacharjee D; Ganguly S; Reddy J; Ahuja V; Panduga V; Parab M; Vishwas KG; Kumar N; Balganesh M; Balasubramanian V
Antimicrob Agents Chemother; 2013 Jun; 57(6):2506-10. PubMed ID: 23507276
[TBL] [Abstract][Full Text] [Related]
2. Is there a place for β-lactams in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis? Synergy between meropenem and amoxicillin/clavulanate.
Gonzalo X; Drobniewski F
J Antimicrob Chemother; 2013 Feb; 68(2):366-9. PubMed ID: 23070734
[TBL] [Abstract][Full Text] [Related]
3. In Vitro Activity of β-Lactams in Combination with β-Lactamase Inhibitors against Multidrug-Resistant Mycobacterium tuberculosis Isolates.
Zhang D; Wang Y; Lu J; Pang Y
Antimicrob Agents Chemother; 2016 Jan; 60(1):393-9. PubMed ID: 26525785
[TBL] [Abstract][Full Text] [Related]
4. Activity of faropenem with and without rifampicin against Mycobacterium tuberculosis: evaluation in a whole-blood bactericidal activity trial.
Gurumurthy M; Verma R; Naftalin CM; Hee KH; Lu Q; Tan KH; Issac S; Lin W; Tan A; Seng KY; Lee LS; Paton NI
J Antimicrob Chemother; 2017 Jul; 72(7):2012-2019. PubMed ID: 28333342
[TBL] [Abstract][Full Text] [Related]
5. Meropenem-clavulanic acid shows activity against Mycobacterium tuberculosis in vivo.
England K; Boshoff HI; Arora K; Weiner D; Dayao E; Schimel D; Via LE; Barry CE
Antimicrob Agents Chemother; 2012 Jun; 56(6):3384-7. PubMed ID: 22450968
[TBL] [Abstract][Full Text] [Related]
6. Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters.
Cavanaugh JS; Jou R; Wu MH; Dalton T; Kurbatova E; Ershova J; Cegielski JP;
J Antimicrob Chemother; 2017 Jun; 72(6):1678-1687. PubMed ID: 28333192
[TBL] [Abstract][Full Text] [Related]
7. Identification of Mycobacterial Genes Involved in Antibiotic Sensitivity: Implications for the Treatment of Tuberculosis with β-Lactam-Containing Regimens.
Viswanathan G; Yadav S; Raghunand TR
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28438925
[TBL] [Abstract][Full Text] [Related]
8. Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis.
Payen MC; De Wit S; Martin C; Sergysels R; Muylle I; Van Laethem Y; Clumeck N
Int J Tuberc Lung Dis; 2012 Apr; 16(4):558-60. PubMed ID: 22325421
[TBL] [Abstract][Full Text] [Related]
9. Meropenem-clavulanate has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.
Davies Forsman L; Giske CG; Bruchfeld J; Schön T; Juréen P; Ängeby K
Int J Mycobacteriol; 2015 Mar; 4 Suppl 1():80-1. PubMed ID: 27128620
[TBL] [Abstract][Full Text] [Related]
10. [
Shi J; Zheng DW; Ma XG; Su RY; Zhu YK; Wang SH; Chang WJ; Sun GQ; Sun DY
Zhonghua Jie He He Hu Xi Za Zhi; 2023 Aug; 46(8):797-805. PubMed ID: 37536990
[No Abstract] [Full Text] [Related]
11. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis.
Hugonnet JE; Tremblay LW; Boshoff HI; Barry CE; Blanchard JS
Science; 2009 Feb; 323(5918):1215-8. PubMed ID: 19251630
[TBL] [Abstract][Full Text] [Related]
12. Paradoxical Hypersusceptibility of Drug-resistant Mycobacteriumtuberculosis to β-lactam Antibiotics.
Cohen KA; El-Hay T; Wyres KL; Weissbrod O; Munsamy V; Yanover C; Aharonov R; Shaham O; Conway TC; Goldschmidt Y; Bishai WR; Pym AS
EBioMedicine; 2016 Jul; 9():170-179. PubMed ID: 27333036
[TBL] [Abstract][Full Text] [Related]
13. Ethambutol and meropenem/clavulanate synergy promotes enhanced extracellular and intracellular killing of
Olivença F; Pires D; Silveiro C; Gama B; Holtreman F; Anes E; Catalão MJ
Antimicrob Agents Chemother; 2024 Apr; 68(4):e0158623. PubMed ID: 38411952
[TBL] [Abstract][Full Text] [Related]
14. How Long Does Antimycobacterial Antibiotic-loaded Bone Cement Have In Vitro Activity for Musculoskeletal Tuberculosis?
Lee JH; Han CD; Cho SN; Yang IH; Lee WS; Baek SH; Shin JW; Husein KEI; Park KK
Clin Orthop Relat Res; 2017 Nov; 475(11):2795-2804. PubMed ID: 28795294
[TBL] [Abstract][Full Text] [Related]
15. Can inhibitor-resistant substitutions in the Mycobacterium tuberculosis β-Lactamase BlaC lead to clavulanate resistance?: a biochemical rationale for the use of β-lactam-β-lactamase inhibitor combinations.
Kurz SG; Wolff KA; Hazra S; Bethel CR; Hujer AM; Smith KM; Xu Y; Tremblay LW; Blanchard JS; Nguyen L; Bonomo RA
Antimicrob Agents Chemother; 2013 Dec; 57(12):6085-96. PubMed ID: 24060876
[TBL] [Abstract][Full Text] [Related]
16. Activity of amoxicillin/clavulanate in patients with tuberculosis.
Chambers HF; Kocagöz T; Sipit T; Turner J; Hopewell PC
Clin Infect Dis; 1998 Apr; 26(4):874-7. PubMed ID: 9564467
[TBL] [Abstract][Full Text] [Related]
17. The vitro efficacy of beta-lactam and beta-lactamase inhibitors against multidrug resistant clinical strains of Mycobacterium tuberculosis.
Dinçer I; Ergin A; Kocagöz T
Int J Antimicrob Agents; 2004 Apr; 23(4):408-11. PubMed ID: 15081094
[TBL] [Abstract][Full Text] [Related]
18. Activity of carbapenems combined with clavulanate against murine tuberculosis.
Veziris N; Truffot C; Mainardi JL; Jarlier V
Antimicrob Agents Chemother; 2011 Jun; 55(6):2597-600. PubMed ID: 21402832
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of β-lactam killing and resistance in the context of Mycobacterium tuberculosis.
Wivagg CN; Bhattacharyya RP; Hung DT
J Antibiot (Tokyo); 2014 Sep; 67(9):645-54. PubMed ID: 25052484
[TBL] [Abstract][Full Text] [Related]
20. Ertapenem and Faropenem against Mycobacterium tuberculosis: in vitro testing and comparison by macro and microdilution.
Gonzalo X; Satta G; Ortiz Canseco J; McHugh TD; Drobniewski F
BMC Microbiol; 2020 Aug; 20(1):271. PubMed ID: 32867678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
